Latest Breaking News On - Division for nephrology - Page 1 : vimarsana.com

Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023

Two-year results from both PROTECT and DUPLEX pivotal Phase 3 studies demonstrate treatment with sparsentan has the potential to preserve kidney function and significantly delay time to kidney.

United statesMichellen rheaultBrad rovinNivi nehraNaomi eichenbaumJula inrigOhio state university centerDivision for nephrologyTravere therapeutics incAmerican society of nephrologyDivision of pediatric nephrologyExchange commissionCorporate communicationsClinical research managementUniversity of minnesota medical schoolAmerican society

Travere Therapeutics (TVTX) Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM

Travere Therapeutics (TVTX) Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesBrad rovinJula inrigMichellen rheaultDivision of pediatric nephrologyTravere therapeutics incOhio state university centerDivision for nephrologyUniversity of minnesota medical schoolAmerican society of nephrologyClinical research managementTravere therapeuticsAmerican societyKidney weekNew england journalMedical director

PROTECT: Sparsentan Outperforms Irbesartan in IgA Nephropathy

The 2-year data from the PROTECT study confirms the sustained benefit of sparsentan in patients with IgA nephropathy.

United statesBrad rovinCampbellp sparsentanJula inrigNational institute of diabetesOhio state university brad rovinAmerican society of nephrologyKidney function decline on health careTravere therapeutics incOhio state universityAmerican society of nephrology kidney weekDivision for nephrologyClinical research managementAmerican societyNephrology kidney weekOhio state

Long-Term Data Confirm Benefit of Sparsentan in IgA Nephropathy

Results from a confirmatory study evaluating sparsentan in patients with primary IgAN showed that the treatment was associated with kidney function preservation.

Brad rovinDivision for nephrologyDrug administrationOhio state university centerClinical research managementMedical directorTravere therapeuticsNew drug application

Long-Term Data Confirm Benefit of Sparsentan in IgA Nephropathy

Results from a confirmatory study evaluating sparsentan in patients with primary IgAN showed that the treatment was associated with kidney function preservation.

Brad rovinDrug administrationDivision for nephrologyClinical research managementOhio state university centerMedical directorTravere therapeuticsNew drug application